F. Hoffmann-La Roche Ltd (manufacturing of unpackaged product, primary packaging (bottling stage), quality control testing, secondary packaging, batch release; manufacturing of unpackaged product, primary packaging (bottling stage), quality control testing (microbiological purity testing))

The drug is indicated for the treatment of 5q-associated spinal muscular atrophy (SMA) in pediatric and adult patients.

Dosage form: powder for oral solution

ATC: M09AX10